Skip to main content
Equibles
ZBIO logo

ZBIO · Zenas BioPharma, Inc.

Track ZBIO — free

Use ZBIO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ZBIO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$33.04 -0.73 (-2.16%) At close · Aug 26
Market Cap
$2.06B
Shares
65.18M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$33.04 Open$33.80 Day$31.91–33.99 52W close$15.20–43.17 Avg vol 30d775K Short int11.7M · 17.9% float · 21.1d Short vol80% Last earningsMar 16, 2026 DataSep 2024–Aug 2026 Filing10-Q · Aug 13

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.64
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +27%
above
Price vs 50-day avg +14%
above
RSI (14) 59
neutral
MACD trend Negative
52-week position 64%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +6%
trailing
6-month return +31%
trailing
YTD return −9%
this year
Relative strength +18%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $29 › 200d $26 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
17.89% of float · ▼ -0.8% MoM · 21.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
146 holders — near 2-yr high, broad support
Squeeze score 82
high risk · 0–100
Fundamentals
Strong
Revenue growth +100%
Y/Y
EPS growth +29%
Y/Y
Free cash flow $-172.4M
Balance sheet $32.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 110%
annualized · 1-yr
Max drawdown −65%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+27% Bullish
Price vs 50-day avg
+14% Bullish
RSI (14)
59 Neutral
MACD trend
Negative Bearish
52-week position
64% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $29 › 200d $26 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
17.89% of float · ▼ -0.8% MoM · 21.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
146 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $15 Now $33 · 64% Range high $43
vs 200-day avg +27% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and investments $673.9M as of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZBIO
Zenas BioPharma, Inc.
this stock
$2.06B -9.0% +100.0% — 17.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.72B +20.7% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.89B +5.6% +20.8% 20.2 2.3%
ARGX
Argenx SE
 $63.81B +24.5% — — 1.9%
CSLLY
Csl Ltd
 $60.07B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
146
% held
94.4%
Net QoQ
+3.5M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
156
View
Short & Settlement
Short Interest Falling
Shares short
11.7M
Days to cover
21.1d
Change
-94.6K sh
View
Short Volume
Short vol %
80%
As of
Aug 26, 2026
Short Total
View
Fails to Deliver
FTD shares
292
Value
$9.1K
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
52.7%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$10.0M
Net income (FY)
$-377.7M
EPS diluted
$-8.44
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
10
View
Exempt Offerings
Offering
$200.1M
Filed
May 14, 2024
View
Earnings & Events
Earnings Calls
Last call
Mar 16, 2026
View

Performance

5D 20D 120D MTD YTD
ZBIO +5.7% +6.3% +30.8% +5.1% -9.0%
SPY -0.4% +5.0% +12.4% +2.6% +12.3%
vs SPY +6.1% +1.3% +18.4% +2.5% -21.4%
Key facts CIK 1953926 CUSIP 98937L105 13F (30d) 137 filings 134 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)